Nuvalent Inc (NUVL)
70.95
-1.69
(-2.33%)
USD |
NASDAQ |
May 17, 16:00
70.95
0.00 (0.00%)
Pre-Market: 20:00
Nuvalent Net Income (Quarterly): -44.48M for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -44.48M |
| December 31, 2023 | -38.29M |
| September 30, 2023 | -33.64M |
| June 30, 2023 | -29.09M |
| March 31, 2023 | -25.19M |
| December 31, 2022 | -26.12M |
| September 30, 2022 | -19.72M |
| June 30, 2022 | -18.47M |
| March 31, 2022 | -17.55M |
| Date | Value |
|---|---|
| December 31, 2021 | -17.29M |
| September 30, 2021 | -12.43M |
| June 30, 2021 | -9.838M |
| March 31, 2021 | -6.785M |
| December 31, 2020 | -6.58M |
| September 30, 2020 | -4.778M |
| June 30, 2020 | -8.557M |
| March 31, 2020 | 5.359M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-44.48M
Minimum
Mar 2024
5.359M
Maximum
Mar 2020
-18.44M
Average
-17.55M
Median
Mar 2022
Net Income (Quarterly) Benchmarks
| Geron Corp | -55.39M |
| Verastem Inc | -33.86M |
| Karyopharm Therapeutics Inc | -37.36M |
| Syndax Pharmaceuticals Inc | -72.40M |
| AnaptysBio Inc | -43.94M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 52.59M |
| EPS Diluted (Quarterly) | -0.69 |
| Enterprise Value | 3.884B |
| Earnings Yield | -3.40% |